搜索临床试验以:R-CEOP-90
总计2514个结果
-
Ruijin Hospital未知
-
Nanjing Yoko Biomedical Co., Ltd.招聘中
-
Dana-Farber Cancer InstituteGenentech, Inc.招聘中
-
Fondazione Italiana Linfomi ONLUS未知
-
Nordic Lymphoma GroupRoche Pharma AG招聘中弥漫性大 B 细胞淋巴瘤 | DLBCL芬兰, 挪威, 丹麦, 意大利, 瑞典, 澳大利亚, 新西兰
-
Shandong Cancer Hospital and InstituteThe First Affiliated Hospital of Nanchang University招聘中
-
Shandong Provincial Hospital招聘中套细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤 | 高级 B 细胞淋巴瘤,未另行说明 | 具有 MYC 和 BCL2 和/或 BCL6 重排的高级别 B 细胞淋巴瘤 | B细胞非霍奇金淋巴瘤中国
-
Johnson & Johnson Pharmaceutical Research & Development...完全的急性髓性白血病
-
AHS Cancer Control AlbertaHoffmann-La Roche完全的
-
Second Affiliated Hospital, School of Medicine,...Ningbo Medical Center Lihuili Hospital; Huizhou Municipal Central Hospital; Taizhou Hospital of... 和其他合作者招聘中
-
First Affiliated Hospital of Zhejiang University未知
-
Fudan University招聘中
-
Asan Medical Center邀请报名
-
Denovo Biopharma LLC完全的
-
Prof. Dr. M. Dreyling (co-chairman)LMU Klinikum招聘中
-
Cancer Institute and Hospital, Chinese Academy...未知弥漫性大 B 细胞淋巴瘤 | 信蒂利单抗 | TP53突变
-
University Hospital MuensterBayer主动,不招人
-
OHSU Knight Cancer InstituteOregon Health and Science University; Boston Scientific Corporation完全的
-
The Lymphoma Academic Research OrganisationFrench Innovative Leukemia Organisation完全的
-
Emory UniversityNational Cancer Institute (NCI); Sirtex Medical撤销
-
Massachusetts General HospitalNational Institutes of Health (NIH); Implant Sciences终止
-
Johns Hopkins University终止液体复苏 | 烧伤任何程度,涉及体表的 20-29% | 烧伤任何程度,涉及体表的 30-39% | 烧伤任何程度,涉及 40-49% 的身体表面 | 烧伤任何程度,涉及体表的 50-59% | 烧伤任何程度,涉及 60-65% 的身体表面美国
-
Beijing InnoCare Pharma Tech Co., Ltd.招聘中
-
Prof. Dr. Clemens SchmittCharite University, Berlin, Germany; Janssen-Cilag Ltd.主动,不招人
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)完全的